HK Stock Market Move | WUXI BIO (02269) rose more than 4%, with a 56% increase in mid-term net profit compared to the same period last year. The company has raised its full-year revenue guidance.

WUXI BIO (02269) rose more than 4%, as of the time of release, it increased by 4.03% to HK$30.98, with a turnover of HK$4.44 billion. On the news front, WUXI BIO announced its interim performance for 2025. The company achieved a revenue of 9.95 billion yuan, up 16.1% year-on-year. The gross profit margin for the period increased by 3.6 percentage points to 42.7%. Net profit increased by 54.8% to 2.76 billion yuan, driving the net profit attributable to owners of the company up by 56.0% to 2.34 billion yuan. Adjusted net profit increased by 11.6% to 2.84 billion yuan year-on-year. At the same time, WUXI BIO announced an upward adjustment of its full-year revenue guidance for 2025 to 14%-16%. In the first half of 2025, WUXI BIO signed 86 new integrated projects, setting a new record for the period and pushing the total number of integrated projects to 864. Among them, the number of phase III clinical and commercialization projects increased to 67 and 24 respectively, with a 24.9% year-on-year increase in revenue from phase III clinical and commercialization production. In terms of order backlog, the company's total uncompleted service orders amount to $20.34 billion, with a future uncompleted order scale of over $42.1 billion in the next 3 years.